Articles
Prolonged Controlled-Release of Nafarelin, a Luteinizing Hormone-Releasing Hormone Analogue, from Biodegradable Polymeric Implants: Influence of Composition and Molecular Weight of Polymer

https://doi.org/10.1002/jps.2600750407Get rights and content

Abstract

The release of the peptide hormone nafarelin, 5-oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-3-(2-naphthyl)-d- alanyl-l-leucyl-l-arginyl-l-prolylglycinamide, a potent luteinizing hormone-releasing hormone (LHRH) agonist, from implants of the biodegradable copolymer poly(d,l-lactide-co-glycolide) (PLGA) has been studied both in vivo and in vitro. The release has a triphasic profile typical for bulk-eroding monolithic controlled-release systems, characterized by a secondary phase of lower release preceded and followed by phases of higher release. The primary factor controlling the peptide release profile is polymer erosion, which in turn may be controlled by modifying physical properties of the polymer such as the molecular weight or the ratio of the more hydrophobic lactic acid monomer to the less hydrophobic glycolic acid monomer. The duration of the secondary phase has been found to be directly proportional to the molecular weight of the copolymer, and the total duration as well as the duration of the secondary phase are both directly proportional to the monomer ratio. A system has been identified in which the secondary phase is sufficiently reduced to provide essentially continuous efficacy in the rat for greater then eight months, with partially effective levels of release of nafarelin continuing beyond 15 months.

References and Notes (21)

  • L.R. Beck et al.

    Am. J. Obstet. Gynecol.

    (1983)
  • L.M. Sanders et al.

    J. Pharm. Sci.

    (1984)
  • S.T. Anik et al.

    Int. J. Pharm.

    (1983)
  • N.A. Higgins

    Condensation Polymers of Hydroxyacetic Acid

    (1954)
  • J.M. Brady et al.

    J. Biomed. Mater. Res.

    (1973)
  • D.E. Cutright et al.

    USDC National Technical Information Service Report

    (1976)
  • R.K. Kulkarni et al.

    Arch. Surg.

    (1966)
  • A.K. Schneider

    Polylactide Sutures

    (1972)
  • E.S. Nuwayser et al.

    Trans. Am. Soc. Artif. Intern. Organs

    (1975)
  • G.A. Boswell et al.

    Polylactide Drug Mixtures

    (1973)
There are more references available in the full text version of this article.

Cited by (143)

  • Implantable drug delivery systems: An overview

    2018, Nanostructures for the Engineering of Cells, Tissues and Organs: From Design to Applications
  • Parenteral Delivery of Peptides and Proteins

    2011, Challenges in Delivery of Therapeutic Genomics and Proteomics
  • Cationic and thermosensitive protamine conjugated gels for enhancing sustained human growth hormone delivery

    2010, Biomaterials
    Citation Excerpt :

    The most investigated method is an encapsulation of hGH to poly(lactic acid-co-glycolic acid) (PLGA) microsphere. PLGA is a biodegradable polymer and approved in market for sustained release formulation of peptides such as luteinizing hormone-releasing hormone (LHRH) analogues [11,12]. However, developing sustained release formulation of proteins including hGH has been hampered due to their complex structure which is related to protein activity.

  • The reliable targeting of specific drug release profiles by integrating arrays of different albumin-encapsulated microsphere types

    2009, Biomaterials
    Citation Excerpt :

    Because the release rate is dependent on physical or chemical properties of the releasing medium, researchers have proposed various design parameters that can be modulated to achieve desired release profiles. These parameters include polymer composition [3], molecular weight [4], particle size [5,6], physical configuration [7], level of protein loading [8], and polymer concentration in the organic solvent during microsphere preparation [9]. It has also been reported that stable release from biodegradable microspheres could be successfully obtained by conjugating the drug to the polymer matrix [10], or by providing an outer layer that surrounds the core unit containing the drug [11].

View all citing articles on Scopus
View full text